HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Soldano Ferrone Selected Research

Heterophile Antibodies

1/2005HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage.
8/2003Immunoproteasome subunits LMP2 and LMP7 downregulation in primary malignant melanoma lesions: association with lack of spontaneous regression.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Soldano Ferrone Research Topics

Disease

208Neoplasms (Cancer)
03/2022 - 01/2002
92Melanoma (Melanoma, Malignant)
01/2022 - 11/2002
24Neoplasm Metastasis (Metastasis)
01/2022 - 02/2004
22Disease Progression
01/2022 - 05/2003
18Breast Neoplasms (Breast Cancer)
04/2020 - 11/2007
13Carcinoma (Carcinomatosis)
02/2016 - 11/2002
11Colorectal Neoplasms (Colorectal Cancer)
01/2020 - 03/2004
10Squamous Cell Carcinoma of Head and Neck
11/2016 - 01/2005
9Glioblastoma (Glioblastoma Multiforme)
01/2021 - 12/2005
9Ovarian Neoplasms (Ovarian Cancer)
09/2020 - 09/2007
9Neuroblastoma
11/2019 - 09/2004
9Head and Neck Neoplasms (Head and Neck Cancer)
01/2018 - 01/2005
7Adenocarcinoma
01/2021 - 03/2004
6Renal Cell Carcinoma (Grawitz Tumor)
11/2016 - 05/2003
5Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2021 - 11/2002
5Sarcoma (Soft Tissue Sarcoma)
12/2020 - 09/2002
5Squamous Cell Carcinoma (Epidermoid Carcinoma)
02/2020 - 05/2003
5Leukemia
01/2016 - 04/2004
4Alcoholism (Alcohol Abuse)
04/2020 - 06/2014
4Triple Negative Breast Neoplasms
01/2020 - 10/2010
3Chordoma
01/2021 - 03/2009
3Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2021 - 11/2016
3Prostatic Neoplasms (Prostate Cancer)
01/2021 - 04/2009
3Pancreatic Neoplasms (Pancreatic Cancer)
01/2018 - 11/2017
2Microsatellite Instability
01/2022 - 02/2007

Drug/Important Bio-Agent (IBA)

59Histocompatibility Antigens Class IIBA
01/2021 - 05/2003
57AntigensIBA
01/2022 - 05/2003
49Monoclonal AntibodiesIBA
01/2022 - 11/2002
33Proteins (Proteins, Gene)FDA Link
01/2021 - 11/2002
28HLA Antigens (Human Leukocyte Antigens)IBA
01/2021 - 04/2004
26Biomarkers (Surrogate Marker)IBA
01/2022 - 09/2005
26Neoplasm Antigens (Tumor Antigens)IBA
01/2021 - 06/2003
24Peptides (Polypeptides)IBA
01/2021 - 05/2003
20AntibodiesIBA
01/2021 - 01/2004
20HMW-MAAIBA
11/2011 - 01/2004
15Chimeric Antigen ReceptorsIBA
07/2021 - 04/2010
14tapasinIBA
10/2017 - 05/2003
13chondroitin sulfate proteoglycan 4IBA
01/2022 - 01/2010
13LigandsIBA
01/2021 - 11/2002
13EpitopesIBA
01/2018 - 06/2003
12CytokinesIBA
12/2020 - 08/2004
11VaccinesIBA
01/2021 - 08/2004
10HLA-A Antigens (HLA-A)IBA
01/2022 - 02/2005
9Immune Checkpoint InhibitorsIBA
03/2022 - 02/2016
9ParaffinIBA
01/2021 - 09/2003
9Cetuximab (Erbitux)FDA Link
01/2020 - 11/2009
9Chondroitin Sulfate ProteoglycansIBA
01/2019 - 01/2004
9Proteoglycans (Proteoglycan)IBA
01/2019 - 08/2009
9HLA-G Antigens (HLA G)IBA
02/2013 - 02/2003
7InterferonsIBA
01/2021 - 02/2011
7Pharmaceutical PreparationsIBA
04/2020 - 08/2009
7Messenger RNA (mRNA)IBA
01/2020 - 04/2003
6ErbB Receptors (EGF Receptor)IBA
03/2022 - 10/2010
6IpilimumabIBA
01/2022 - 07/2012
6RNA (Ribonucleic Acid)IBA
01/2019 - 11/2008
6Biological ProductsIBA
01/2019 - 01/2004
6Histocompatibility Antigens Class IIIBA
01/2017 - 12/2005
5HLA-B Antigens (HLA-B)IBA
01/2022 - 02/2005
5Formaldehyde (Formol)FDA Link
01/2021 - 05/2003
5Aldehyde DehydrogenaseIBA
01/2020 - 10/2011
5CalnexinIBA
10/2017 - 12/2005
5Melanoma-Specific AntigensIBA
09/2016 - 04/2004
5Complement System Proteins (Complement)IBA
08/2015 - 12/2004
5transporter associated with antigen processing (TAP)IBA
06/2012 - 05/2003
4Histone Deacetylase InhibitorsIBA
03/2022 - 02/2016
4Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
03/2022 - 06/2012
4DNA (Deoxyribonucleic Acid)IBA
03/2022 - 07/2005
4Surface Antigens (Surface Antigen)IBA
01/2021 - 01/2002
4Small Interfering RNA (siRNA)IBA
01/2019 - 06/2012
4Cancer VaccinesIBA
01/2018 - 04/2006
4Chondroitin Sulfates (Chondroitin Sulfate)IBA
01/2015 - 06/2011
4CalreticulinIBA
01/2014 - 12/2005
4micaIBA
07/2009 - 11/2002
3VemurafenibIBA
01/2021 - 07/2012
3Immunoglobulins (Immunoglobulin)IBA
10/2020 - 04/2005
3Interleukin-15 (Interleukin 15)IBA
10/2020 - 09/2005
3Disulfiram (Antabuse)FDA Link
04/2020 - 11/2017
3Panitumumab (Vectibix)FDA Link
01/2020 - 11/2016
3EnzymesIBA
08/2019 - 02/2010
3Immunoglobulin G (IgG)IBA
10/2018 - 12/2007
3T-Cell Antigen Receptors (T-Cell Receptor)IBA
11/2016 - 06/2003
3Interleukin-2 (IL2)IBA
01/2016 - 08/2005
3GD2 gangliosideIBA
08/2015 - 04/2005
3HLA-DR Antigens (HLA-DR)IBA
01/2014 - 07/2007
3Codon (Codons)IBA
04/2013 - 03/2004
3Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA
06/2012 - 06/2004
3Proteasome Endopeptidase Complex (Proteasome)IBA
02/2012 - 04/2005
3Phosphotransferases (Kinase)IBA
12/2011 - 03/2007
3Therapeutic UsesIBA
01/2010 - 12/2004
3GangliosidesIBA
04/2009 - 09/2002
3beta 2-Microglobulin (beta 2 Microglobulin)IBA
06/2008 - 02/2004
3HLA-A2 Antigen (HLA A2 Antigen)IBA
12/2005 - 02/2005
2MethyltransferasesIBA
03/2022 - 07/2005
2I-antigenIBA
01/2022 - 01/2020

Therapy/Procedure

91Immunotherapy
01/2022 - 06/2003
63Therapeutics
03/2022 - 01/2004
16Drug Therapy (Chemotherapy)
03/2022 - 04/2004
12Radiotherapy
03/2022 - 01/2005
4Neoadjuvant Therapy
01/2022 - 03/2012
4Radioimmunotherapy
01/2020 - 04/2017